Home » Bio-investments
At CLONEX, we operate at the intersection of biology and capital markets, identifying opportunities where breakthrough science meets market inefficiency.
CLONEX Biotech Trading Initiative is a specialized division focused on navigating the dynamic and high-potential biotechnology market. Unlike traditional equity strategies, we concentrate exclusively on biotechnology companies, where scientific innovation, emerging technologies, and market events create unique trading opportunities.
Biotech trading is high risk and volatile.
Past performance ≠ future results
Trading around clinical trials, FDA decisions, and major announcements.
Identifying companies with scalable biotechnology technologies.
Monitoring funding, dilution, and institutional investment flows.
Early identification of disruptive biotech startups and IPO opportunities.
Company | Sector | Focus Area |
|---|---|---|
Illumina | Genomics | DNA sequencing technologies |
CRISPR Therapeutics | Gene Editing | CRISPR-based therapies |
Twist Bioscience | Synthetic Biology | DNA synthesis platform |
10x Genomics | Bioinformatics | Single-cell analysis |
Pacific Biosciences | Sequencing | Long-read sequencing |
Biotechnology remains one of the fastest-growing sectors globally, driven by rapid scientific advancements, increasing healthcare demands, and the convergence of artificial intelligence with biological research.
transforming healthcare and biotechnology
of companies advancing clinical pipelines globally
invested annually into biotech innovation
Access high-growth opportunities in the future of biology. Science drives innovation while we navigate the markets.
Copyright 2025. All rights reserved by CLONEX (M) SDN. BHD. SSM: 202301051929 (1545843-W).